Shumakov V I, Kazakov E N, Semenovskiĭ M L, Khubutiia A Sh, Kormer A Ia, Nikolaenko E M, Chestukhin V V, Kolpakov E V, Zimin N K, Dolbin A G
Grud Serdechnososudistaia Khir. 1990(5):8-12.
The article analyses the first clinical experience in orthotopic allotransplantation of the heart at the Scientific Research Institute of Transplantology and Artificial Organs, USSR Ministry of Health, in the period from October, 1986 to July, 1989 (26 transplantations of the heart and one two-stage transplantation of the heart with the use of "Poisk-10M" artificial heart for 3.5 days in the first stage). Eleven patients are alive. Follow-up periods: maximum over 2.5 years, minimum 3 months. Sixteen patients died in different periods (up to 12 months). Three-component therapy (cyclosporine A, methylprednisolone, azathioprine) was applied for immunosuppression. The authors analyse the problems of the selection of potential recipients (indications and contraindications) and donor, the optimum surgical techniques, complications of immunosuppressive therapy, and infectious complications. The first clinical experience in two-stage transplantation of the heart is analysed. The first experience in transplantation of the heart in patients allows the conclusion that the use of this method for the management of the terminal stage of congestive cardiac insufficiency is a reality.
本文分析了苏联卫生部移植学与人工器官科研所在1986年10月至1989年7月期间进行心脏原位同种异体移植的首次临床经验（26例心脏移植及1例心脏两阶段移植，第一阶段使用“Poisk - 10M”人工心脏3.5天）。11例患者存活。随访期：最长超过2.5年，最短3个月。16例患者在不同时期死亡（至12个月）。采用三联疗法（环孢素A、甲泼尼龙、硫唑嘌呤）进行免疫抑制。作者分析了潜在受者（适应证和禁忌证）及供者的选择问题、最佳手术技术、免疫抑制治疗的并发症以及感染性并发症。对心脏两阶段移植的首次临床经验进行了分析。心脏移植患者的首次经验表明，使用这种方法治疗充血性心力衰竭终末期是可行的。
